SURGERY PARTNERS, INC. and Bain Capital Conclude Discussions
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- Japan has no plans to overhaul pension funds' asset allocation, sources say
Surgery Partners (SGRY) guidance reaffirmation 'positive' despite no Bain deal - Mizuho
June 17, 2025 3:22 PM EDTMizuho analyst Ann Hynes reiterated an Outperform rating and a $28.00 price target on Surgery Partners (NASDAQ: SGRY) amid today's sell-off, following the company's announcement that it has concluded its discussions with Bain Capital regarding a potential acquisition. The company's independent committee determined that its long-term potential as an independent, publicly-traded company... More
